# CStone Pharmaceuticals clinical trials: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with CStone Pharmaceuticals as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CStone Pharmaceuticals: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cstone-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07938814 | A First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938814) |
| June 3, 2026 | NCT07622524 | A Phase I Study of CS5007 in Participants With Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1 | Recruiting | Advanced Solid Tumors | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622524) |
| December 19, 2024 | NCT06741644 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06741644) |
| January 26, 2023 | NCT05700448 | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma | CStone Pharmaceuticals | Phase 3 | Not yet recruiting | Extranodal NK/T-cell Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05700448) |
| May 19, 2022 | NCT05381753 | Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World | CStone Pharmaceuticals | Observational | Completed | Gastrointestinal Stromal Tumors | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05381753) |
| March 28, 2022 | NCT05297890 | A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer | CStone Pharmaceuticals | Phase 2 | Active not recruiting | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05297890) |
| March 15, 2022 | NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | CStone Pharmaceuticals | Phase 1 | Suspended | Advanced Solid Tumor, Advanced Lymphoma | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05279300) |
| June 9, 2020 | NCT04421352 | Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients | CStone Pharmaceuticals | Phase 1 | Completed | Relapsed Small Cell Lung Cancer | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04421352) |
| April 8, 2020 | NCT04338724 | A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1 | Completed | Advanced Solid Tumor | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04338724) |
| February 5, 2020 | NCT04254939 | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | CStone Pharmaceuticals | Phase 1/2 | Completed | Gastrointestinal Stromal Tumors | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04254939) |
| January 18, 2020 | NCT04233060 | A Study of CS3005 in Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1 | Completed | Advanced Solid Tumor | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04233060) |
| December 16, 2019 | NCT04200404 | A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | CStone Pharmaceuticals | Phase 1/2 | Completed | Advanced Refractory Solid Tumors | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04200404) |
| December 11, 2019 | NCT04194801 | A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma | CStone Pharmaceuticals | Phase 1/2 | Completed | Hepatocellular Carcinoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04194801) |
| December 11, 2019 | NCT04194775 | A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | CStone Pharmaceuticals | Phase 3 | Active not recruiting | Hepatocellular Carcinoma | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04194775) |
| December 5, 2019 | NCT04187352 | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma | CStone Pharmaceuticals | Phase 3 | Completed | Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04187352) |
| November 25, 2019 | NCT04176393 | A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation | CStone Pharmaceuticals | Phase 1 | Completed | Relapsed or Refractory Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04176393) |
| November 14, 2019 | NCT04162301 | A Study of CS3002 in Subjects With Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1 | Terminated | Advanced Solid Tumor | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04162301) |
| January 18, 2019 | NCT03809767 | A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas | CStone Pharmaceuticals | Phase 1 | Completed | Solid Tumor, Lymphoma | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03809767) |
| January 14, 2019 | NCT03802591 | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | CStone Pharmaceuticals | Phase 3 | Completed | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 479 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03802591) |
| December 28, 2018 | NCT03789604 | A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer | CStone Pharmaceuticals | Phase 3 | Completed | Non Small Cell Lung Cancer | 479 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03789604) |
| November 16, 2018 | NCT03744403 | A Study of CS1001 in Subjects with Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1 | Completed | Advanced Solid Tumors | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03744403) |
| November 9, 2018 | NCT03736850 | Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors | CStone Pharmaceuticals | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumors | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03736850) |
| November 2, 2018 | NCT03728556 | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | CStone Pharmaceuticals | Phase 3 | Completed | Non-Small Cell Lung Cancer Stage III | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03728556) |
| July 23, 2018 | NCT03595657 | A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) | CStone Pharmaceuticals | Phase 2 | Completed | Extranodal Natural Killer/T-Cell Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03595657) |
| May 14, 2018 | NCT03523819 | A Study of CS1002 in Subjects with Advanced Solid Tumors | CStone Pharmaceuticals | Phase 1 | Completed | Solid Tumor, Adult | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03523819) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 5 |
| Phase 2 | 3 |
| Phase 3 | 6 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Recruiting | 2 |
| Active not recruiting | 2 |
| Not yet recruiting | 2 |
| Terminated | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Hepatocellular | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Gastrointestinal Stromal Tumors | 2 |
| Recurrence | 2 |
| Hodgkin Disease | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Small Cell Lung Carcinoma | 1 |
| Lymphoma | 1 |
| Lymphoma, Extranodal NK-T-Cell | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Furniture manufacturers in the United States](https://specstream.ai/data/businesses/furniture-manufacturers/united-states)
- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
- [Soup restaurants in the United States](https://specstream.ai/data/businesses/soup-restaurants/united-states)
- [Lighting fixture manufacturers in the United States](https://specstream.ai/data/businesses/lighting-fixture-manufacturers/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
